Interplay between inflammatory bowel disease therapeutics and the gut microbiome reveals opportunities for novel treatment approaches

Simple item page
dc.contributor.authorO’Reilly, Catherineen
dc.contributor.authorMills, Susanen
dc.contributor.authorRea, Mary C.en
dc.contributor.authorLavelle, Aonghusen
dc.contributor.authorGhosh, Subrataen
dc.contributor.authorHill, Colinen
dc.contributor.authorRoss, R. Paulen
dc.contributor.funderScience Foundation Irelanden
dc.date.accessioned2024-03-13T15:59:16Z
dc.date.available2024-03-13T15:59:16Z
dc.date.issued2023en
dc.description.abstractInflammatory bowel disease (IBD) is a complex heterogeneous disorder defined by recurring chronic inflammation of the gastrointestinal tract, attributed to a combination of factors including genetic susceptibility, altered immune response, a shift in microbial composition/microbial insults (infection/exposure), and environmental influences. Therapeutics generally used to treat IBD mainly focus on the immune response and include non-specific anti-inflammatory and immunosuppressive therapeutics and targeted therapeutics aimed at specific components of the immune system. Other therapies include exclusive enteral nutrition and emerging stem cell therapies. However, in recent years, scientists have begun to examine the interplay between these therapeutics and the gut microbiome, and we present this information here. Many of these therapeutics are associated with alterations to gut microbiome composition and functionality, often driving it toward a “healthier profile” and preclinical studies have revealed that such alterations can play an important role in therapeutic efficacy. The gut microbiome can also improve or hinder IBD therapeutic efficacy or generate undesirable metabolites. For certain IBD therapeutics, the microbiome composition, particularly before treatment, may serve as a biomarker of therapeutic efficacy. Utilising this information and manipulating the interactions between the gut microbiome and IBD therapeutics may enhance treatment outcomes in the future and bring about new opportunities for personalised, precision medicine.en
dc.description.statusPeer revieweden
dc.description.versionPublished Versionen
dc.format.mimetypeapplication/pdfen
dc.identifier.articleid35en
dc.identifier.citationO’Reilly, C., Mills, S., Rea, M.C., Lavelle, A., Ghosh, S., Hill, C. and Ross, R.P. (2023) ‘Interplay between inflammatory bowel disease therapeutics and the gut microbiome reveals opportunities for novel treatment approaches’, Microbiome Research Reports, 2(4), 35, (27pp). doi: 10.20517/mrr.2023.41en
dc.identifier.doi10.20517/mrr.2023.41en
dc.identifier.endpage27en
dc.identifier.issued4en
dc.identifier.journaltitleMicrobiome Research Reportsen
dc.identifier.startpage1en
dc.identifier.urihttps://hdl.handle.net/10468/15675
dc.identifier.volume2en
dc.language.isoenen
dc.publisherOAE Publishing Inc.en
dc.relation.projectinfo:eu-repo/grantAgreement/SFI/SFI Research Centres/12/RC/2273/IE/Alimentary Pharmabiotic Centre (APC) - Interfacing Food & Medicine/en
dc.rights© The Author(s) 2023. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, sharing, adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.en
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/en
dc.subjectInflammatory bowel diseaseen
dc.subjectGut microbiomeen
dc.subjectIBD therapeuticsen
dc.subjectAnti-inflammatory therapiesen
dc.subjectImmunosuppressive therapiesen
dc.subjectRespondersen
dc.subjectNon-respondersen
dc.titleInterplay between inflammatory bowel disease therapeutics and the gut microbiome reveals opportunities for novel treatment approachesen
dc.typeArticle (peer-reviewed)en
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
mrr2041_down.pdf
Size:
1.8 MB
Format:
Adobe Portable Document Format
Description:
Published Version
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
2.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
APC Microbiome Ireland - Journal Articles